Skip to main content
Premium Trial:

Request an Annual Quote

Peter Lundberg Goes to Solexa from ABI; Nicholas Conti Becomes VP of Corporate Development for Orchid; Deborah Oronzio, Sandra Sonnessa New VP s at Gentris; James Merryweather Joins Ciphergen as VP for Pharma Corporate Development; and Others

Solexa announced a number of management changes last week. Peter Lundberg has joined the company as vice president and chief technical officer. Most recently, he was vice president for DNA platforms R&D at Applied Biosytems. Lundberg holds an MBA from the Universityof Connecticut, as well as BS and MS degrees in engineering physics from Chalmers Technical University in Sweden.

 

Tony Smith, until recently chief technology officer of Solexa, has been promoted to vice president and chief scientific officer. He will continue to be responsible for all research and development activities in the UK.

 

Mary Schramke, formerly head of product development at Lynx Therapeutics and the company's interim chief executive officer, has become vice president and general manager of genomic services of Solexa.


 

Nicholas Contihas become vice president of corporate development of Orchid BioSciences, a new position, the company said last week. Most recently, he was vice president for research and development and business operations of a new unit at Becton Dickinson.


 

Deborah Oronzio has joined Gentris as vice president of business development and marketing, and Sandra Sonnessa as vice president of corporate development, the company said yesterday.

 

Oronzio previously held managerial positions at PPD/PPGx, Becton Dickinson, and Pharmacia Diagnostics, among other companies. She holds an MS in business management from Johns Hopkins University and a BS degree in medical technology.

 

Sonnessa, prior to joining Gentris, held positions with Innovative Health Solutions, Bristol-Myers Squibb and other companies. She holds an MBA from Northwestern University and an MS in maternal-child health nursing from the University of Pittsburgh.


 

James Merryweather has become executive vice president for pharmaceutical corporate development at Ciphergen Biosystems, the company said on Monday. Prior to joining Ciphergen, he was executive vice president of business development and commercial operations at Incyte. Before that, he was vice president for program management at Millennium Pharmaceuticals. Merryweather holds a PhD in biochemistry from Washington State University and a BS in chemistry from Northern Illinois University.


 

Walter Moos has joined SRI International of Menlo Park, Calif., as vice president of its biosciences division, SRI said on Monday. Most recently, he was chairman and CEO of MitoKor. Prior to that, he was a corporate vice president at Chiron. Moos holds a PhD in chemistry from the Universityof California, Berkeley, and an AB in chemistry from Harvard University. SRI's biosciences division provides research services for NIH and pharmaceutical companies.


 

Mark Roellig has joined Fisher Scientific as vice president, general counsel, and secretary, replacing Todd DuChene, who resigned "to pursue other interests," the Hampton, NH-based company said on Monday.

 

Roellig comes from Storage Technology, StorageTek, where he held the same positions. He holds a law degree from George Washington University, an MBA from the Universityof Washington in Seattle, and a bachelor's degree in mathematics from the Universityof Michigan.


 

MelTec of Magdeburg, Germany, announced a number of management changes on Tuesday. Norbert Diehl will be the company's new CEO, replacing Walter Schubert, who will join MelTec's board of directors and remain a company consultant. Marcus Hammerle has become vice president of research and development, Ronald Koop was appointed as vice president of business development, Peter Karcher has become vice president of bioinformatics and data analysis, and Lars Philipsen has become vice president of technology.


 

David Tiemeier has become chief commercial officer of Kalypsys, the San Diego-based company said last week. Prior to joining Kalypsys, he was vice president of licensing and development at Immtech International and vice president of business development at NeoPharm.

 

Kalypys further said on Tuesday that Philip Needleman and August Watanabe have joined its board of directors.

 

Needleman was most recently senior executive vice president, chief scientist, and chairman of research and development of Pharmacia.

 

Watanabe is a former senior executive of Eli Lilly, where he was executive vice president of science and technology, and president of Lilly Research Laboratories.


 

The Oracle Life Sciences User Group has elected its first board of directors. Members are: Judith Bandy, vice president of marketing, InforSense; John Burke, research software administrator, UCB Group; Mark Forster, chemical informatics systems team leader, Syngenta; William Hayes, associate director of research informatics, Biogen Idec; Jack Leunissen, professor of bioinformatics, Wageningen University; Mahendra Navarange, executive consultant, Atos Origin; Kevin Prime, director of quality assurance, Elsevier MDL; Martin Widlake, database services manager, Wellcome Trust Sanger Institute; Charlie Berger, senior director of product management, life sciences and data mining technologies, Oracle; Raf Podowski, senior product manager, life sciences, Oracle; and Mary Arbelaez, director of business development, Oracle.


 

Dale Wahlstrom will chair the board of directors of the BioBusiness Alliance of Minnesota, the organization said on Monday. He is the vice president of Medtronic Cardiac Rhythm Management Ventures. Other members include Tim Mulcahy, vice president for research at the University of Minnesota, and Eric Wieben, director for genomics research at Mayo Clinic.


 

Marc Caron, a professor of cell biology at Duke University Medical Center, has been awarded the 2005 Achievement Award of the Society for Biomolecular Screening. Caron co-founded Norak Biosciences (now Xsira Pharmaceuticals), and he was one of the co-developers of that company's flagship Transfluor fluorescent assay technology. From 1992 to 2004, he was an investigator of the Howard Hughes Medical Institute.


 

David Dood, president and CEO of Serologicals, has received the Oglethorpe Sword from the British American Business Group of Atlanta, Serologicals said yesterday. Every year an American or British citizen who has contributed to Anglo-Georgia interests is awarded the sword.


 

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected]to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.